logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Panel on Cost-Effectiveness in Health and Medicine recommendations : Identifying costs. Discussion.

    Article, Communication - En anglais

    Symposium "Pharmacoeconomic Factors Related to the Treatment of Schizophrenia". Chicago, IL, USA, 1998/04/08.

    The assignment of costs in a cost-effectiveness analysis is a complex and disputed issue.

    The Panel on Cost-Effectiveness in Health and Medicine was convened to discuss standards that could be applied across a range of areas of cost-effectiveness.

    Additionally, the Panel had a mandate to resolve some controversial issues about the practice of cost-effectiveness that created difficulty in making comparisons across studies.

    The Panel proposed these guidelines :

    • (1) Do at least some of the analysis from a social perspective ;

    • (2) Assign values to resources that reflect their opportunity costs ;

    • (3) Avoid zero counting of resources ;

    • (4) Avoid double counting of resources ;

    • (5) Make analyses only as exacting as necessary in a study.

    Difficulties in data collection were discussed.

    Among other questions considered by the panel were how to assign a value to the patient's time and which productivity costs to include in a cost-effectiveness analysis.

    With tools and suggestions from the Panel on Cost-Effectiveness in Health and Medicine, the cost analyst can report costs accurately and provide accurate comparisons of cost performance across states, trial modalities, or diseases.

    Mots-clés Pascal : Schizophrénie, Trouble psychiatrique, Chimiothérapie, Traitement, Neuroleptique, Psychotrope, Recommandation, Analyse coût efficacité, Analyse coût, Economie santé, Homme, Psychose

    Mots-clés Pascal anglais : Schizophrenia, Mental disorder, Chemotherapy, Treatment, Neuroleptic, Psychotropic, Recommendation, Cost efficiency analysis, Cost analysis, Health economy, Human, Psychosis

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0189467

    Code Inist : 002B02B03. Création : 16/11/1999.